JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US Labor Department's OSHA Revokes COVID-19 Vaccination Order for Large Employers

01/25/2022 | 02:14pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.09% 179.46 Delayed Quote.5.00%
MODERNA, INC. 3.78% 135.8 Delayed Quote.-48.48%
PFIZER, INC. 0.52% 53.99 Delayed Quote.-9.04%
All news about JOHNSON & JOHNSON
07:11aLegend Biotech Receives Conditional European Commission Approval for Multiple Myeloma D..
MT
05/25JOHNSON & JOHNSON : to Provide Webcast Fireside Chat on Clinical Data to be Presented at t..
PU
05/25Tentative $161.5M settlement reached in WVa opioid trial
AQ
05/25Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA (guselkumab) and L..
AQ
05/25Nigeria Receives 4.4 Million Doses of Covid-19 Vaccines
AQ
05/24JOHNSON & JOHNSON : Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® ..
PU
05/24TRANSCRIPT : Johnson & Johnson Presents at UBS Global Healthcare Conference, May-24-2022 1..
CI
05/23Bayer's Xarelto Shows Long-Term Effect in Heart Disease Patients
MT
05/23JOHNSON & JOHNSON : New Data From Two Large Studies Reinforce Effectiveness of Dual Pathwa..
PU
05/23What We're Reading This Week
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 451 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,2x
Yield 2022 2,48%
Capitalization 473 B 473 B -
EV / Sales 2022 4,81x
EV / Sales 2023 4,53x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 179,62 $
Average target price 187,75 $
Spread / Average Target 4,53%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530
NOVO NORDISK A/S0.49%240 761